Remission, response, retention and persistence to treatment with disease-modifying agents in patients with rheumatoid arthritis: a study of harmonised Swedish, Danish and Norwegian cohorts
Authors' conclusion
Harmonisation of data from different RA data sources can be achieved without compromising internal validity or generalisability. The low proportions reaching remission, point to an unmet need for treatment optimisation in RA.
Study context
- Population
- Patients with rheumatoid arthritis (RA) in eight large-scale clinical RA registers and a pragmatic trial from Sweden, Denmark and Norwaycohorts ≈50 to 22,000 patients
- Exposure
- MTX monotherapy vs tumour necrosis factor inhibitors (TNFi) vs rituximab
- Outcome
- Retention, persistence and remission
- Follow-up
- 1 year
Methodological detailsharmonised registers and pragmatic trial data, Sweden, Denmark and Norway, 36 months of follow-up
- Harmonised registers and pragmatic trial data
- Sweden, Denmark and Norway
- 36 months of follow-up
Main finding
As reported in the abstract
Retention and persistence rates high
>50% at 1 year
Remained on drug without other disease-modifying antirheumatic drugs (DMARDs) added and achieved ACR/EULAR or SDAI remission, MTX or TNFi starters
<33%
Remained on drug without other DMARDs added and achieved ACR/EULAR or SDAI remission, rituximab starters
10%
Observational data: associations, not effects.
Original publication
Remission, response, retention and persistence to treatment with disease-modifying agents in patients with rheumatoid arthritis: a study of harmonised Swedish, Danish and Norwegian cohorts. RMD Open. Published 6 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →